Eli Lillys Retatrutide Achieves 28% Weight Loss in Pivotal Trial, Intensifying Obesity Drug Race Eli Lilly (LLY) cleared a major clinical milestone this week, reporting that its next-generation obesity treatment Retatrutide helped patients shed an average of 28.3% of their body weight in a late-stage study
"I've been on Zepbound since October and have lost 40 pounds so far
Available to anyone in Lubbock County
doi: 10.1507/endocrj.EJ25-0087, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar] 15
How Wegovy Works in the Body Wegovy is a brand-name prescription medication containing the active ingredient semaglutide
Merriam, Effects of Eight Months Treatment with Graded Doses of a Growth Hormone (GH)-Releasing Peptide in GH-Deficient Children, The Journal of Clinical Endocrinology & Metabolism, Volume 83, Issue 7, 1 July 1998, Pages 23552360 (3) Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R